Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
49 hedge funds and large institutions have $1.43M invested in Navidea Biopharmaceuticals Inc. in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 12 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
41% more capital invested
Capital invested by funds: $1.02M → $1.43M (+$414K)
13% less funds holding
Funds holding: 56 → 49 (-7)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.2K |
| 2 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$22.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18.1K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$15.5K |
| 5 |
VF
Virtu Financial
New York
|
+$13.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$7K |
| 2 |
Jane Street
New York
|
-$5K |
| 3 |
SWA
Stratos Wealth Advisors
Beachwood,
Ohio
|
-$5K |
| 4 |
CAG
Csenge Advisory Group
Clearwater,
Florida
|
-$4K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SS
51
Simplicity Solutions
Minneapolis,
Minnesota
| – | -$2K | -760 | Closed |
|
52
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$2K | -750 | Closed |
|
|
AG
53
Advisor Group
Phoenix,
Arizona
| – | -$221 | -75 | -75% |
|
54
Simplex Trading
Chicago,
Illinois
| – | +$15 | +5 | New |
|
NAVB Hedge Fund Activity: Q1 2019 in Review
49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2019, worth a combined $1.43M — up 41% from $1.02M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NAVB and 5 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $39.2K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $7K sold.
- 49 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2019, down from 56 in Q4 2018.
- Funds reported $1.43M of Navidea Biopharmaceuticals Inc. stock for Q1 2019, up 41% quarter-over-quarter.
- 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2019 and 12 closed out, a net change of -7 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2019 was Vanguard Group, an estimated $39.2K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2019 was Two Sigma Securities, an estimated $7K sold.
Based on aggregated 13F filings for Q1 2019.